Clinical Trial Update: A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing osimertinib plus selumetinib in EGFR-mutant, EGFR-inhibitor naive advanced non-small cell lung cancer is currently active but not recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• Selumetinib (selumetinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING